Monitor for any future amendments converting this 13G to a 13D, which would signal an activist intent. The filing is passive, but the involvement of David L. Kanen, who has a history of activist campaigns, warrants attention for potential escalation.
Price Chart
Executive Summary
Philotimo Fund, LP, along with related entities Kanen Wealth Management LLC and David L. Kanen, filed a new Schedule 13G disclosing aggregate beneficial ownership of 2,280,518 shares of Apyx Medical Corp, representing approximately 5.4% of outstanding shares. The filing certifies a passive investment intent with no plan to influence or change control of the company.
Key Financial Metrics
Key Facts
- Philotimo Fund, LP, Philotimo Focused Growth & Income Fund, Kanen Wealth Management LLC, and David L. Kanen collectively own 2,280,518 shares of Apyx Medical Corp common stock.
- The aggregate stake represents approximately 5.4% of the 42,124,023 shares outstanding as of August 5, 2026.
- Philotimo Fund directly owns 1,425,473 shares (3.4%), and Philotimo Focused Growth & Income Fund directly owns 855,045 shares (2.0%).
- Kanen Wealth Management LLC is the general partner of Philotimo Fund and investment manager of the Focused Growth & Income Fund, and David L. Kanen is the managing member of Kanen Wealth Management.
- This is a new Schedule 13G filing (not an amendment), indicating a new 5%+ passive stake disclosure.
- The filing includes a certification under Rule 13d-1(c) that the securities were not acquired with the purpose or effect of changing or influencing control of the issuer.
Financial Impact
Stake valued at approximately $5.6 million based on market cap of $104M and 5.4% ownership.
Risk Factors
- Potential future conversion to Schedule 13D if the investor shifts to an activist stance.
- Concentrated ownership by a single group could influence shareholder votes or corporate actions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0001688522-26-000006 |
| Document: 0001688522-26-000006-index.html | 0001688522-26-000006 |
| Document: 0001688522-26-000006.txt | 0001688522-26-000006 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 1d ago | SC 13G | $2.61 | awaiting T+20 | awaiting T+20 | $2.69 (+3.07%) |
Oct 22, 2026 7d ago | Press Release | $2.41 | awaiting T+20 | awaiting T+20 | $2.69 (+11.62%) |
Aug 7, 2026 11w ago | 8-K | $3.46 $3.05 | ▼ −11.85% | ▼ −10.94% | $2.69 (−22.25%) |
May 21, 2026 23w ago | 8-K | $4.13 $3.95 | ▼ −4.36% | ▼ −2.94% | $2.69 (−34.87%) |
May 21, 2026 23w ago | Press Release | $4.25 $4.04 | ▼ −4.94% | ▼ −5.27% | $2.69 (−36.71%) |
May 14, 2026 24w ago | 8-K | $4.36 $4.69 | ▲ +7.57% | ▲ +8.43% | $2.69 (−38.30%) |
May 11, 2026 24w ago | 8-K | $3.92 $4.86 | ▲ +23.98% | ▲ +24.28% | $2.69 (−31.38%) |
Apr 23, 2026 27w ago | Press Release | $3.80 $3.79 | ▼ −0.26% | ▼ −4.90% | $2.69 (−29.21%) |
Mar 10, 2026 33w ago | Press Release | $3.45 $3.81 | ▲ +10.43% | ▲ +10.59% | $2.69 (−22.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers